ArticleBMC complementary medicine and therapies2026
Integrative bioinformatics and preliminary experimental validation suggest the therapeutic potential of lycorine in uterine corpus endometrial carcinoma.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Uterine corpus endometrial carcinoma (UCEC) is one of the most prevalent gynecological malignancies worldwide and remains a significant threat to women's health. Lycorine, a natural alkaloid isolated from plants of the Amaryllidaceae family, has attracted considerable attention owing to its diverse pharmacological activities, particularly its anti-tumor properties. However, the potential therapeutic targets and action mechanism of lycorine in UCEC remain unclear.In this study, an integrated strategy combining bioinformatic analysis and preliminary experimental validation was used to elucidate the anti-tumor mechanisms of lycorine in UCEC. Potential targets of lycorine were predicted using public databases and intersected with differentially expressed genes derived from The Cancer Genome Atlas (TCGA) UCEC dataset. Subsequently, a protein-protein interaction (PPI) network was constructed, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to investigate the biological functions and pathways associated with these targets. Prognostic analysis and Cox regression were used to establish a risk prediction model. Immune infiltration analysis was performed to evaluate the relationship between key genes and the tumor immune microenvironment.Results revealed 10 potential targets of lycorine associated with UCEC. Functional enrichment analysis indicated that these genes were mainly involved in cholinergic synapse and neuroactive ligand-receptor interaction pathways. Three key genes (ACHE, MAN2B1, and PNP) were further identified to construct a prognostic model, which showed moderate predictive performance in survival analysis. Immune infiltration analysis revealed that these genes were associated with multiple immune cell populations in the tumor microenvironment. Molecular docking revealed that the binding energies of ACHE, MAN2B1, and PNP with lycorine were ≤ - 7.0 kcal/mol, indicating stable binding. In vitro experiments confirmed that lycorine significantly inhibited the proliferation of Ishikawa endometrial cancer cells.In conclusion, this study provides new insights into the potential therapeutic effects of lycorine in UCEC and identifies ACHE, MAN2B1, and PNP as promising therapeutic targets for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.